RE:RE:More comments on Biogen's aducanumab And then he ends with this. Doesn't sound very promising. Pun intended.
"A favorable ruling from the FDA would likely be a blow to other companies trying a different approach. For one thing, Biogen would no longer have to consider partnerships or buyouts. For another, the pursuit of anti-amyloid treatments for Alzheimer’s disease would likely once again overshadow those pursuing a different path. If approved, many people will applaud the decision as a big step forward in the treatment of Alzheimer’s disease, but in hindsight it would probably be a major step backwards."